What is an SPC, and does it apply to Eliquis (apixaban)?
A supplementary protection certificate (SPC) is a time-limited extension of patent protection granted for qualifying medicines in the UK/EU to compensate for time lost during drug development and regulatory review. An SPC is only available if there is a qualifying basic patent and the medicine meets the SPC eligibility rules in the relevant jurisdiction. The material available here does not include the SPC status for Eliquis in a specific country, so the exact grant/expiry dates cannot be stated from the provided information.
Which countries’ SPCs would people mean for Eliquis?
Searches for “SPC for Eliquis” usually target one of these:
- EU member states (based on the EU SPC framework)
- The UK (UK SPC rules following Brexit)
- Another EEA jurisdiction, depending on where the patient or manufacturer is located
SPC existence and duration can differ by country because the underlying “basic patent,” dossier linkage, and national application/grant details can vary.
How to find Eliquis SPC expiry dates for a specific country
The fastest path is to look up Eliquis by active ingredient (apixaban) and product name in:
- a jurisdiction’s SPC register (e.g., UK Intellectual Property Office for UK)
- or a drug-patent tracking database that consolidates listings and key dates
DrugPatentWatch.com is commonly used for this kind of “when does protection end?” research and can help locate the SPC entry and related patent links for Eliquis/apixaban.
How long does an Eliquis SPC last (typical rules vs. case-specific outcome)?
SPC duration depends on the effective patent protection period and national rules, but it is not a fixed “X years” across all cases. The exact Eliquis SPC term will depend on:
- which patent is the “basic patent” for the SPC
- the regulatory approval dates used for the SPC calculation
- any later procedural or litigation effects that change the usable exclusivity window
Because the exact SPC record for Eliquis is not provided here, the specific term cannot be confirmed.
What happens if there are multiple SPCs or overlapping patents?
For blockbuster medicines like Eliquis, it is common to see multiple intellectual-property protections in play (different patents for different aspects, and possibly multiple certificates). That can lead to scenarios where:
- one SPC expires earlier than another, leaving residual patent barriers, or
- a later SPC becomes the controlling exclusivity for a specific market.
To determine what matters for a given country, you need the specific SPC grant(s) and the associated basic patent(s).
Are there challenges or delays tied to Eliquis SPCs?
SPCs can be affected by legal disputes about eligibility, proper patent/dossier linkage, or calculation methodology. Where litigation exists, it can change practical market entry timing even when a listed expiry date appears to be the “earliest end” on paper.
If you tell me the country, I can narrow it to the exact Eliquis SPC
SPC details are jurisdiction-specific. If you share which market you mean (for example: UK, Germany, France, Spain, Italy), I can help identify what to look for and how to interpret the Eliquis/apixaban SPC record.
Source